Peringatan Keamanan

Withdrawn from the US market in 1999 due to associations with QTc prolongation and adverse cardiovascular events.

Grepafloxacin

DB00365

small molecule approved investigational withdrawn

Deskripsi

Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.

Struktur Molekul 2D

Berat 359.3947
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 15 ± 3 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly and extensively absorbed following oral administration. The absolute bioavailability is approximately 70%.

Metabolisme

Primarily hepatic via CYP1A2 and CYP3A4. The major metabolite is a glucuronide conjugate; minor metabolites include sulfate conjugates and oxidative metabolites. The oxidative metabolites are formed mainly by the cytochrome P450 enzyme CYP1A2, while the cytochrome P450 enzyme CYP3A4 plays a minor role. The nonconjugated metabolites have little antimicrobial activity compared with the parent drug, and the conjugated metabolites have no antimicrobial activity

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid caffeine.
  • 2. Drink plenty of fluids.
  • 3. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1151 Data
Deferasirox The serum concentration of Grepafloxacin can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Grepafloxacin can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Grepafloxacin can be decreased when it is combined with Teriflunomide.
Didanosine Didanosine can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Probenecid Probenecid may decrease the excretion rate of Grepafloxacin which could result in a higher serum level.
Quinapril Quinapril can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium acetate Calcium acetate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron Dextran Iron Dextran can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Calcium can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanthanum carbonate Lanthanum carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric carboxymaltose Ferric carboxymaltose can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron sucrose Iron sucrose can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphate Ferric pyrophosphate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium citrate Calcium citrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric sulfate Ferric sulfate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric cation Ferric cation can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tetraferric tricitrate decahydrate Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lanthanum III cation Lanthanum III cation can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium polycarbophil Calcium polycarbophil can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric oxyhydroxide Ferric oxyhydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucralfate Sucralfate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Grepafloxacin.
Nitrofurantoin The therapeutic efficacy of Grepafloxacin can be decreased when used in combination with Nitrofurantoin.
Abiraterone The serum concentration of Grepafloxacin can be increased when it is combined with Abiraterone.
Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Grepafloxacin.
Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Grepafloxacin.
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Grepafloxacin.
Insulin human The therapeutic efficacy of Insulin human can be increased when used in combination with Grepafloxacin.
Insulin lispro The therapeutic efficacy of Insulin lispro can be increased when used in combination with Grepafloxacin.
Insulin pork The therapeutic efficacy of Insulin pork can be increased when used in combination with Grepafloxacin.
Troglitazone The therapeutic efficacy of Troglitazone can be increased when used in combination with Grepafloxacin.
Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Grepafloxacin.
Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Grepafloxacin.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Grepafloxacin.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Grepafloxacin.
Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Grepafloxacin.
Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Grepafloxacin.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Grepafloxacin.
Nateglinide The therapeutic efficacy of Nateglinide can be increased when used in combination with Grepafloxacin.
Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Grepafloxacin.
Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Grepafloxacin.
Phenformin The therapeutic efficacy of Phenformin can be increased when used in combination with Grepafloxacin.
Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Grepafloxacin.
Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Grepafloxacin.
Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Grepafloxacin.
Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Grepafloxacin.
Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Grepafloxacin.
Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Grepafloxacin.
Mitiglinide The therapeutic efficacy of Mitiglinide can be increased when used in combination with Grepafloxacin.
Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Grepafloxacin.
Exenatide The therapeutic efficacy of Exenatide can be increased when used in combination with Grepafloxacin.
Mecasermin The therapeutic efficacy of Mecasermin can be increased when used in combination with Grepafloxacin.
Pramlintide The therapeutic efficacy of Pramlintide can be increased when used in combination with Grepafloxacin.
Glisoxepide The therapeutic efficacy of Glisoxepide can be increased when used in combination with Grepafloxacin.
Insulin aspart The therapeutic efficacy of Insulin aspart can be increased when used in combination with Grepafloxacin.
Insulin glulisine The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Grepafloxacin.
Glymidine The therapeutic efficacy of Glymidine can be increased when used in combination with Grepafloxacin.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Grepafloxacin.
Buformin The therapeutic efficacy of Buformin can be increased when used in combination with Grepafloxacin.
Vildagliptin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Grepafloxacin.
Voglibose The therapeutic efficacy of Voglibose can be increased when used in combination with Grepafloxacin.
NN344 The therapeutic efficacy of NN344 can be increased when used in combination with Grepafloxacin.
AMG-222 The therapeutic efficacy of AMG-222 can be increased when used in combination with Grepafloxacin.
Bisegliptin The therapeutic efficacy of Bisegliptin can be increased when used in combination with Grepafloxacin.
Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Grepafloxacin.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Grepafloxacin.
Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Grepafloxacin.
Liraglutide The therapeutic efficacy of Liraglutide can be increased when used in combination with Grepafloxacin.
Gosogliptin The therapeutic efficacy of Gosogliptin can be increased when used in combination with Grepafloxacin.
Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Grepafloxacin.
Glibornuride The therapeutic efficacy of Glibornuride can be increased when used in combination with Grepafloxacin.
Benfluorex The therapeutic efficacy of Benfluorex can be increased when used in combination with Grepafloxacin.
Empagliflozin The therapeutic efficacy of Empagliflozin can be increased when used in combination with Grepafloxacin.
Albiglutide The therapeutic efficacy of Albiglutide can be increased when used in combination with Grepafloxacin.
Dulaglutide The therapeutic efficacy of Dulaglutide can be increased when used in combination with Grepafloxacin.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Grepafloxacin.
Netoglitazone The therapeutic efficacy of Netoglitazone can be increased when used in combination with Grepafloxacin.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Grepafloxacin.
Ciglitazone The therapeutic efficacy of Ciglitazone can be increased when used in combination with Grepafloxacin.
Lixisenatide The therapeutic efficacy of Lixisenatide can be increased when used in combination with Grepafloxacin.
Insulin beef The therapeutic efficacy of Insulin beef can be increased when used in combination with Grepafloxacin.
Insulin degludec The therapeutic efficacy of Insulin degludec can be increased when used in combination with Grepafloxacin.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be increased when used in combination with Grepafloxacin.
Insulin tregopil The therapeutic efficacy of Insulin tregopil can be increased when used in combination with Grepafloxacin.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Grepafloxacin.
Dutogliptin The therapeutic efficacy of Dutogliptin can be increased when used in combination with Grepafloxacin.
Allicin The therapeutic efficacy of Allicin can be increased when used in combination with Grepafloxacin.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Grepafloxacin.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Grepafloxacin.
Teneligliptin The therapeutic efficacy of Teneligliptin can be increased when used in combination with Grepafloxacin.
Omarigliptin The therapeutic efficacy of Omarigliptin can be increased when used in combination with Grepafloxacin.
Carmegliptin The therapeutic efficacy of Carmegliptin can be increased when used in combination with Grepafloxacin.
Gemigliptin The therapeutic efficacy of Gemigliptin can be increased when used in combination with Grepafloxacin.
Anagliptin The therapeutic efficacy of Anagliptin can be increased when used in combination with Grepafloxacin.
Evogliptin The therapeutic efficacy of Evogliptin can be increased when used in combination with Grepafloxacin.
Sotagliflozin The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Grepafloxacin.

Target Protein

DNA gyrase subunit A gyrA
DNA gyrase subunit B gyrB
DNA gyrase subunit A gyrA
DNA topoisomerase 4 subunit A parC

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Raxar
    Tablet • 200 mg / tab • Oral • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul